BR9807076A - Tratamento de esclerose múltipla mediante ingestão ou inalação de copolìmero-1 - Google Patents

Tratamento de esclerose múltipla mediante ingestão ou inalação de copolìmero-1

Info

Publication number
BR9807076A
BR9807076A BR9807076-2A BR9807076A BR9807076A BR 9807076 A BR9807076 A BR 9807076A BR 9807076 A BR9807076 A BR 9807076A BR 9807076 A BR9807076 A BR 9807076A
Authority
BR
Brazil
Prior art keywords
treatment
multiple sclerosis
ingestion
inhalation
copolymer
Prior art date
Application number
BR9807076-2A
Other languages
English (en)
Other versions
BR9807076B1 (pt
BRPI9807076B8 (pt
Inventor
Ruth Arnon
Michael Sela
Dvora Teitelbaum
Adrian Gilbert
Milka Linenberg
Rvka Riven Kreitman
Original Assignee
Yeda Reserach And Dev Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Reserach And Dev Co Ltd filed Critical Yeda Reserach And Dev Co Ltd
Publication of BR9807076A publication Critical patent/BR9807076A/pt
Publication of BR9807076B1 publication Critical patent/BR9807076B1/pt
Publication of BRPI9807076B8 publication Critical patent/BRPI9807076B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
  • Peptides Or Proteins (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)

Abstract

''TRATAMENTO DE ESCLEROSE MúLTIPLA MEDIANTE INGESTãO OU INALAçãO DE COPOLìMERO-1'' A presente invenção se refere ao tratamento de esclerose múltipla pela ingestão ou inalação de copolímero-1 e a composições farmacêuticas utilizáveis para esse tratamento.
BRPI9807076A 1997-01-10 1998-01-12 "uso de acetato de glatirâmero para a fabricação de medicamento para o tratamento de esclerose múltipla e composição farmacêutica" BRPI9807076B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL11998997A IL119989A0 (en) 1997-01-10 1997-01-10 Pharmaceutical compositions for oral treatment of multiple sclerosis
PCT/US1998/000375 WO1998030227A1 (en) 1997-01-10 1998-01-12 Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1

Publications (3)

Publication Number Publication Date
BR9807076A true BR9807076A (pt) 2000-05-02
BR9807076B1 BR9807076B1 (pt) 2013-10-29
BRPI9807076B8 BRPI9807076B8 (pt) 2021-05-25

Family

ID=11069682

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9807076A BRPI9807076B8 (pt) 1997-01-10 1998-01-12 "uso de acetato de glatirâmero para a fabricação de medicamento para o tratamento de esclerose múltipla e composição farmacêutica"

Country Status (19)

Country Link
EP (1) EP0975351B1 (pt)
JP (1) JP4216342B2 (pt)
KR (1) KR20000070058A (pt)
CN (1) CN100528222C (pt)
AT (1) ATE356608T1 (pt)
AU (1) AU737287B2 (pt)
BR (1) BRPI9807076B8 (pt)
CA (1) CA2277365C (pt)
CZ (1) CZ297983B6 (pt)
DE (1) DE69837324T2 (pt)
EA (1) EA003128B1 (pt)
HK (1) HK1025737A1 (pt)
HU (1) HU226612B1 (pt)
IL (2) IL119989A0 (pt)
NZ (1) NZ336690A (pt)
PL (1) PL193300B1 (pt)
SK (1) SK284029B6 (pt)
WO (1) WO1998030227A1 (pt)
ZA (1) ZA98214B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL141021A0 (en) 1998-07-23 2002-02-10 Yeda Res & Dev Treatment of autoimmune conditions with copolymer 1 and related copolymers
AU766498B2 (en) * 1998-07-23 2003-10-16 President And Fellows Of Harvard College, The Synthetic peptides and methods of use for autoimmune disease therapies
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6872739B1 (en) * 1999-06-04 2005-03-29 Vereniging Voor Christelijk Wetenshappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis
DE60017733T2 (de) * 1999-06-04 2006-01-12 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Verwendung von riluzol zur behandlung multipler sklerose
US7022663B2 (en) 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
CN1221281C (zh) * 2000-02-18 2005-10-05 耶达研究与开发有限公司 共聚物1的口服、鼻部和肺部用剂型
AU7528001A (en) * 2000-06-05 2001-12-17 Teva Pharma The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
CA2469393C (en) 2001-12-04 2010-05-25 Teva Pharmaceutical Industries, Ltd. Processes for the measurement of the potency of glatiramer acetate
MXPA04008267A (es) 2002-02-25 2004-11-10 Elan Pharm Inc Administracion de agentes para el tratamiento de la inflamacion.
MXPA05007843A (es) * 2003-01-24 2005-10-18 Elan Pharm Inc Composicion y tratamiento de enfermedades desmielinizantes y paralisis por administracion de agentes de remielinizantes.
US7560100B2 (en) 2004-09-09 2009-07-14 Yeda Research And Development Co., Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases
DK2949335T3 (en) 2009-08-20 2017-07-31 Yeda Res & Dev LOW FREQUENT GLATIRAMER ACETATE THERAPY
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
US8709433B2 (en) 2010-10-11 2014-04-29 Teva Pharmaceutical Industries Ltd. Cytokine biomarkers as predictive biomarkers of clinical response for Glatiramer acetate
TW201326399A (zh) 2011-10-10 2013-07-01 Teva Pharma 用於預測對格拉替雷（ｇｌａｔｉｒａｍｅｒ）醋酸鹽之臨床反應之單核苷酸多型性之判定
EP2906719A4 (en) 2012-10-10 2016-11-09 Teva Pharma PREDICTIVE BIOMARKER FOR CLINICAL REACTION FOR GLATIRAMERACETATE
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CN105884866B (zh) * 2015-01-26 2021-04-20 漳州未名博欣生物医药有限公司 格拉替雷的化学合成方法
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
CN112649537B (zh) * 2015-04-28 2024-03-29 深圳翰宇药业股份有限公司 多肽混合物高效液相色谱分析方法
US11167003B2 (en) 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems
EP3645029B1 (en) 2017-06-26 2023-01-18 Institut Pasteur Treatments to eliminate hiv reservoirs and reduce viral load

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800808A (en) * 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins

Also Published As

Publication number Publication date
ZA98214B (en) 1999-08-11
EP0975351B1 (en) 2007-03-14
DE69837324D1 (de) 2007-04-26
ATE356608T1 (de) 2007-04-15
JP4216342B2 (ja) 2009-01-28
JP2001511121A (ja) 2001-08-07
IL130820A (en) 2007-03-08
PL334566A1 (en) 2000-03-13
SK93199A3 (en) 2000-11-07
HU226612B1 (en) 2009-04-28
IL119989A0 (en) 1997-04-15
NZ336690A (en) 2001-05-25
WO1998030227A1 (en) 1998-07-16
EP0975351A4 (en) 2002-05-15
KR20000070058A (ko) 2000-11-25
CZ243799A3 (cs) 2000-06-14
BR9807076B1 (pt) 2013-10-29
AU5819598A (en) 1998-08-03
CN1249690A (zh) 2000-04-05
EA003128B1 (ru) 2003-02-27
CZ297983B6 (cs) 2007-05-16
HUP0001917A3 (en) 2001-12-28
PL193300B1 (pl) 2007-01-31
HUP0001917A2 (hu) 2000-10-28
CA2277365C (en) 2011-04-12
AU737287B2 (en) 2001-08-16
CN100528222C (zh) 2009-08-19
DE69837324T2 (de) 2007-11-29
EA199900621A1 (ru) 2000-02-28
BRPI9807076B8 (pt) 2021-05-25
SK284029B6 (sk) 2004-08-03
HK1025737A1 (en) 2000-11-24
CA2277365A1 (en) 1998-07-16
EP0975351A1 (en) 2000-02-02

Similar Documents

Publication Publication Date Title
BR9807076A (pt) Tratamento de esclerose múltipla mediante ingestão ou inalação de copolìmero-1
ES2161780T3 (es) Polimeros que ligan fosfato para administracion oral.
BR0116169A (pt) Composto, composição farmacêutica que compreende esse composto, processo para a preparação de uma composição farmacêutica, utilização dos compostos, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii e processo para a preparação do composto.
HUP0101293A2 (hu) AspB28-humán inzulint tartalmazó inhalációs gyógyászati készítmény és alkalmazása
SE9804614D0 (sv) New peptides and use thereof
ATE221783T1 (de) Pharmazeutische zusammensetzungen welche lactobacillus plantarum und arginin beinhalten
ATE365743T1 (de) Immunverstärkende verbindungen
DK0506772T3 (da) Farmaceutisk præparat indeholdende et phosphosukker
HK1068344A1 (en) Dimeric compounds and their use as anti-viral agents
ATE223700T1 (de) Ramoplaninhaltige neue injizierbare arzneizubereitungen
ES2173044A1 (es) Glicina, n-(n-l- -glutamil-3-(nitrosotio)-l-valil) y sus aplicaciones.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 37, INDEFIRO DO PRESENTE PEDIDO, UMA VEZ QUE NAO ATENDE AO REQUISITO DE ATIVIDADE INVENTIVA ( ART. 8O COMBINADO COM O ART. 13 DA LPI 9279/96).

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]

Free format text: DESPACHO: ANULADA A DECISAO DE NEGAR ANUENCIA AO PI ASSINALADO CUJA PUBLICACAO FOI EFETUADA NA RPI 2164 DE 26/06/2012. O PI 9807076-2 DEVERA RETORNAR PARA EXAME TECNICO DE PREVIA ANUENCIA. ESTA ANULACAO TEM COMO BASE A RESOLUCAO- RE NO. 3.255, DE 30/6/2012, PUBLICADA NO DOU EM 31/07/2012.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/10/2013, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/01/1998 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 12/01/2018

B15V Prolongation of time limit allowed